Company intelligence / Profile preview

ResQ Pharma

Chicago, Illinois, United Statesresqpharma.com ↗

Ownership: Private
Employees: ~3
Development stage: Commercial

Overview

LipidRescue Therapy is an investigational lipid emulsion-based antidote designed to treat overdoses and poisonings from various lipophilic drugs. The product has received Orphan Drug Designation from the FDA for local anesthetic systemic toxicity but is not yet approved or authorized by regulatory agencies. Applications for market approval were planned in both the USA and EU.

Therapeutic areas: OtherPsychiatryCardiovascular
Modalities: Lipid emulsion therapyNon-pharmacological therapy (as a drug antidote)
Industry: Biotech

Drug pipeline

1 asset

LipidRescue

Investigational

Indications: Drug toxicity

Partnerships

No major pharmaceutical partnerships publicly disclosed. Member of iBIO's PROPEL, EnterpriseWorks Chicago, Chicago Founders Circle, The BUNKER and MATTER/CIMs.

Beyond the preview

Go deeper on ResQ Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ResQ Pharma.

Explore the full profile